← Leaderboards
Carlos E Milla
University Of Minnesota Twin Cities
$64,986
Attributed
$64,986
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$64,986 · 4
By mechanism
M01$64,986 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of Minnesota Twin Cities
Same institution · by research overlap
- Alan R. Sinaiko$5,509,300
- Julia Steinberger$8,822,882
- Thomas E Nevins$1,442,350
- Ken C Winters$9,872,327
- Dorothy K Hatsukami$58,862,572
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationInhalation Drug AdministrationDosageDrug Administration Rate /DurationCystic FibrosisClinical ResearchRespiratory Disorder ChemotherapyHuman SubjectDrug Screening /EvaluationGene TherapyInterviewLipopolysaccharidesLungPatient Oriented ResearchAdolescence (12-20)Respiratory FunctionAdult Human (21+)Age DifferenceAntibioticsAntibody TiteringClinical Trial Phase IiClinical TrialsCytokine
Grant awards (4)
MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II STUDY OF AEROSOLIZED TG$42,607
M01 · FY2005 · RR
A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 28-DAY STUDY OF IN$7,593
M01 · FY2005 · RR
Safety and Tolerability Study of Aztreonam for Inhalation in Cystic Fibrosis$11,090
M01 · FY2004 · RR
Multi-center, Double-blind, Placebo-controlled, Phase II Study of Aerosolized tg$3,696
M01 · FY2004 · RR